CJC-1295 and Ipamorelin fall into the broader family of growth hormone-releasing compounds via related but distinct mechanisms. Each peptide discussed below has its own body of research. However, no published human studies have tested CJC-1295 and Ipamorelin directly combined with GHRP-2, GHRP-6, BPC-157, Retatrutide, or AOD-9604. This means any comparison herein is based on evaluating the individual evidence base of each compound, not on validated combination data.
CJC-1295 and Ipamorelin vs GHRP-2 and GHRP-6
Ipamorelin, GHRP-2 and GHRP-6 all belong to the same broad family of ghrelin receptor agonists, also known as growth hormone-releasing peptides. Ipamorelin was specifically developed, however, to be more selective than its predecessors. This difference is well-documented in the foundational research literature. In the original pharmacological characterisation of ipamorelin, researchers directly compared it to GHRP-6 and GHRP-2 in animal and early human-like tests. All three stimulated growth hormone release with roughly comparable potency. GHRP-6 and GHRP-2, however, significantly increased cortisol and ACTH – the stress hormone pathway. Ipamorelin, conversely, did not elicit significant increases in either, even at doses over 200 times higher than needed for its growth hormone-releasing effect [1].
This selectivity is the main scientific reason why ipamorelin is generally described in research literature as more sophisticated than older GHRP-2 and GHRP-6 compounds. Triggering a lesser stress hormone response, alongside the intended growth hormone release, is generally considered pharmacologically advantageous.
CJC-1295 works differently. Being a GHRH analogue and not a ghrelin receptor agonist, it acts via a completely separate receptor pathway than any of these three GHRP-type compounds. This is the scientific basis for combining a GHRH analogue with a ghrelin receptor agonist in the first place – regardless of whether that ghrelin receptor partner is ipamorelin, GHRP-2, or GHRP-6. However, no published study has directly compared the results of a „CJC-1295 plus ipamorelin” combination against a „CJC-1295 plus GHRP-6" combination. Any claim that one combination outperforms the other therefore remains untested.
CJC-1295 with BPC-157
CJC-1295 and BPC-157 are frequently discussed together in contexts focused on regeneration. However, as established in an earlier article in this series concerning joint and injury regeneration, they represent fundamentally different categories of peptides. No published human studies have tested them in conjunction. CJC-1295 works by elevating systemic growth hormone and IGF-1 levels [2]. This is an endocrine mechanism with reasonably documented effects on these specific hormonal measurements, but without direct outcome data for tissue healing. BPC-157, on the other hand, has been evaluated in preclinical studies for direct effects on tendon and muscle repair. There is also a small case series in humans examining intra-articular knee injections, although a formal review has described this case series as containing significant methodological flaws and lacking proper controls [3].
Since these two compounds have been researched via entirely separate research pathways and have never been tested together in a controlled human study, any specific „CJC-1295 plus BPC-157" protocol or claimed synergistic benefit reflects informal practice rather than validated science.
CJC-1295 with retatrutide
Retatrutide is a fundamentally different type of compound to CJC-1295. It is important to make this distinction clear before considering any combination. Retatrutide is a triple hormone receptor agonist, acting on GLP-1, GIP and glucagon receptors. It is currently undergoing phase 3 clinical trials for obesity, developed by Eli Lilly. It has demonstrated significant weight loss results in published Phase 2 trials. One peer-reviewed study reported weight reductions of up to 24.2% of body weight after 48 weeks in certain dose groups [4]. According to the latest publicly available information, retatrutide remains an investigational drug. It has not received approval from the FDA, the EMA or any other major medicines regulator. It is not legally available as a prescription medicine outside the context of clinical trials.
CJC-1295, on the other hand, acts via a completely separate growth hormone-releasing hormone pathway, rather than the incretin and glucagon pathways that tirzepatide targets. No published studies have tested the two compounds administered together. Any online discussion of a „CJC-1295 and tirzepatide stack” for fat burning reflects speculative combining of two mechanistically unrelated, individually investigational compounds. This is not a studied protocol. And given that tirzepatide itself is not yet an approved medication, this combination carries additional layers of uncertainty beyond those surrounding CJC-1295 alone.
AOD 9604 vs CJC-1295
AOD-9604 and CJC-1295 both originate from fragments of the growth hormone system. However, they were designed for different purposes and have significantly different clinical research histories that are worth understanding clearly. AOD-9604 is a fragment of human growth hormone, specifically amino acids 176-191. It was developed specifically to isolate the fat-metabolising properties of growth hormone, while minimising effects on growth and blood sugar. It underwent an exceptionally extensive clinical development program for a peptide in this general category, including multiple Phase 2 studies in obese human adults [5].
An early phase 2b study did indeed show a statistically significant weight loss compared to placebo, at a low, 1-milligram oral daily dose [5]. However, a larger, pivotal controlled study did not replicate the statistically significant weight loss effect. The formal pharmaceutical development program for the compound was reportedly discontinued following this outcome. This is a significantly more extensive and mixed human clinical trial history than exists for CJC-1295. CJC-1295's own most significant human outcomes study, in HIV-associated visceral obesity, was not completed at all [6].
In terms of mechanism, AOD-9604 was designed to act more selectively on fat metabolism, with a reduced impact on overall growth hormone-driven processes. CJC-1295 raises growth hormone and IGF-1 more broadly throughout the growth hormone axis. This means the two compounds are not interchangeable, even though both are derived from growth hormone biology. No published studies have tested AOD-9604 and CJC-1295 combined. Given AOD-9604's own mixed efficacy history in dedicated human obesity studies, it would not be accurate to characterise either compound as a clearly superior choice for fat burning based on current evidence.
Limitations of current evidence
The same basic limitation applies to all comparisons in this article. Each individual compound has its own separate research history. Some are reasonably significant – six human clinical trials for AOD-9604, cortisol selectivity data for ipamorelin. Others are quite limited – an unfinished obesity trial for CJC-1295. Still others are entirely separate and unrelated – the incretin pathway mechanism of tirzepatide and its Phase 3 active program.
However, no published studies have directly tested any of these compounds combined with CJC-1295 and Ipamorelin as a combined protocol. Comparative claims about which combination „works better” for any particular purpose are not supported by evidence from direct comparative studies and should be treated as unsubstantiated.
Disclaimer
This content is for educational and informational purposes only and should not be interpreted as medical advice, therapeutic recommendation, or a product comparison recommendation. CJC-1295, ipamorelin, GHRP-2, GHRP-6, BPC-157, AOD-9604, and retatrutide are research compounds or, in the case of retatrutide, still under investigation. None of the growth hormone peptides discussed herein are approved by the FDA or European Medicines Agency for general human use. No published human studies have tested CJC-1295 and ipamorelin combined with any of the other compounds discussed in this article.
References
[1] Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. https://doi.org/10.1530/eje.0.1390552
[2] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536
[3] Mayfield, C. K., Bolia, I. K., Feingold, C. L., Lin, E. H., Liu, J. N., Hatch, G. F. R., Gamradt, S. C., & Weber, A. E. (2026). Injectable peptide therapy: A primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 54(1), 223–229. https://doi.org/10.1177/03635465251357593
[4] Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
[5] Wittert, G. A., Hunter, C. E., Zsombor-Murray, E., et al. (2005). AOD9604, an orally active peptide for the treatment of obesity: Results of a phase 2b study. Diabetes, 54(Suppl. 1), A101.
[6] National Centre for Biotechnology Information. (2026). PubChem Compound Summary for CID 91971820, CJC-1295 [Clinical trial data: NCT00267527 and EudraCT 2005-003797-25]. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/91971820